ELANCO ANIMAL HEALTH INC (ELAN) Stock Price & Overview

NYSE:ELAN • US28414H1032

Current stock price

24.11 USD
+0.25 (+1.05%)
At close:
24.4 USD
+0.29 (+1.2%)
After Hours:

The current stock price of ELAN is 24.11 USD. Today ELAN is up by 1.05%. In the past month the price increased by 3.03%. In the past year, price increased by 185.66%.

ELAN Key Statistics

52-Week Range8.33 - 27.72
Current ELAN stock price positioned within its 52-week range.
1-Month Range22.1 - 25.68
Current ELAN stock price positioned within its 1-month range.
Market Cap
11.987B
P/E
25.38
Fwd P/E
22.91
EPS (TTM)
0.95
Dividend Yield
N/A

ELAN Stock Performance

Today
+1.05%
1 Week
+5.75%
1 Month
+3.03%
3 Months
-1.71%
Longer-term
6 Months +12.56%
1 Year +185.66%
2 Years +83.21%
3 Years +154.59%
5 Years -23.97%
10 Years N/A

ELAN Stock Chart

ELANCO ANIMAL HEALTH INC / ELAN Daily stock chart

ELAN Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to ELAN. When comparing the yearly performance of all stocks, ELAN is one of the better performing stocks in the market, outperforming 95.03% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ELAN Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to ELAN. There are concerns on the financial health of ELAN while its profitability can be described as average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ELAN Earnings

On February 24, 2026 ELAN reported an EPS of 0.13 and a revenue of 1.14B. The company beat EPS expectations (15.04% surprise) and beat revenue expectations (2.6% surprise).

Next Earnings DateMay 5, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported$0.13
Revenue Reported1.144B
EPS Surprise 15.04%
Revenue Surprise 2.60%

ELAN Forecast & Estimates

22 analysts have analysed ELAN and the average price target is 30.18 USD. This implies a price increase of 25.16% is expected in the next year compared to the current price of 24.11.

For the next year, analysts expect an EPS growth of 10.75% and a revenue growth 7.16% for ELAN


Analysts
Analysts85.45
Price Target30.18 (25.18%)
EPS Next Y10.75%
Revenue Next Year7.16%

ELAN Groups

Sector & Classification

ELAN Financial Highlights

Over the last trailing twelve months ELAN reported a non-GAAP Earnings per Share(EPS) of 0.95. The EPS increased by 4.4% compared to the year before.


Income Statements
Revenue(TTM)4.71B
Net Income(TTM)-232.00M
Industry RankSector Rank
PM (TTM) N/A
ROA -1.74%
ROE -3.54%
Debt/Equity 0.6
Chartmill High Growth Momentum
EPS Q2Q%-7.14%
Sales Q2Q%12.16%
EPS 1Y (TTM)4.4%
Revenue 1Y (TTM)6.22%

ELAN Ownership

Ownership
Inst Owners110.27%
Shares497.17M
Float491.03M
Ins Owners1.08%
Short Float %5.2%
Short Ratio4.98

About ELAN

Company Profile

ELAN logo image Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Indianapolis, Indiana and currently employs 9,400 full-time employees. The company went IPO on 2018-09-20. The firm's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). The company has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The firm's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.

Company Info

IPO: 2018-09-20

ELANCO ANIMAL HEALTH INC

450 Elanco Circle

Indianapolis INDIANA 46140 US

CEO: Jeffrey N. Simmons

Employees: 9400

ELAN Company Website

ELAN Investor Relations

Phone: 18773526261

ELANCO ANIMAL HEALTH INC / ELAN FAQ

What does ELANCO ANIMAL HEALTH INC do?

Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Indianapolis, Indiana and currently employs 9,400 full-time employees. The company went IPO on 2018-09-20. The firm's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). The company has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The firm's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.


What is the stock price of ELANCO ANIMAL HEALTH INC today?

The current stock price of ELAN is 24.11 USD. The price increased by 1.05% in the last trading session.


Does ELANCO ANIMAL HEALTH INC pay dividends?

ELAN does not pay a dividend.


What is the ChartMill rating of ELANCO ANIMAL HEALTH INC stock?

ELAN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Can you provide the PE ratio for ELAN stock?

The PE ratio for ELANCO ANIMAL HEALTH INC (ELAN) is 25.38. This is based on the reported non-GAAP earnings per share of 0.95 and the current share price of 24.11 USD.


When does ELANCO ANIMAL HEALTH INC (ELAN) report earnings?

ELANCO ANIMAL HEALTH INC (ELAN) will report earnings on 2026-05-05, before the market open.